Group One Trading’s Outlook Therapeutics OTLK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.9K Sell
121,000
-39,200
-24% -$16.9K ﹤0.01% 5817
2025
Q4
$253K Sell
160,200
-124,300
-44% -$199K ﹤0.01% 4162
2025
Q3
$302K Buy
284,500
+284,200
+94,733% +$491K ﹤0.01% 4223
2025
Q2
$480 Sell
300
-1,500
-83% -$2.39K ﹤0.01% 7665
2025
Q1
$2.2K Sell
1,800
-1,674,500
-100% -$2.94M ﹤0.01% 6974
2024
Q4
$3.17M Buy
1,676,300
+1,636,900
+4,155% +$6.73M 0.01% 1512
2024
Q3
$210K Buy
+39,400
New +$288K ﹤0.01% 3572

Other funds holding OTLK

Group One Trading's OTLK Position: Q1 2026 in Review

Group One Trading increased its Outlook Therapeutics (OTLK) stake by 207% in Q1 2026, buying an estimated $33.1K and bringing the position to 113,701 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5848.

Group One Trading first reported a position in OTLK in Q1 2025 and has held it in 5 quarters since. The position peaked at $58.5K in Q4 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Group One Trading held 113,701 shares of Outlook Therapeutics worth $23.4K as of Q1 2026.
  • Group One Trading bought 76,704 Outlook Therapeutics shares in Q1 2026, an estimated $33.1K.
  • Outlook Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5848 holding.
  • Group One Trading first reported a position in Outlook Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Group One Trading's Outlook Therapeutics position peaked at $58.5K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.